Marketing Authorization Application

Related by string. Market Authorization Application * marketing . markets . market : MARKET WIRE via COMTEX . Stock Market . CERTAIN MARKET FACTORS SUCH / authorizations . Authorizations : share repurchase authorization . submitted Marketing Authorization / Applications . applications : Application Delivery Networking . Oracle Application Server * Marketing Authorization Application MAA *

Related by context. All words. (Click for frequent words.) 84 Marketing Authorization Application MAA 83 Marketing Authorisation Application 75 Biologics License Application 75 Biologics License Application BLA 74 Marketing Authorisation Application MAA 72 Marketing Authorization Applications 72 supplemental Biologics License Application 70 Biologic License Application 70 MAA submission 70 Complete Response 70 Market Authorization Application 70 sBLA 69 Marketing Authorization 69 Orphan Drug Status 69 BLA submission 69 Biological License Application 69 Application MAA 69 Biologic License Application BLA 68 FDA Approvable Letter 68 orphan designation 68 alvimopan 68 Rhucin R 68 Orphan Drug status 68 Orathecin 68 Rhucin ® 68 FDA Accepts 67 New Drug Application 67 Marketing Authorisation 67 Phase III Clinical Trial 67 BLA filing 67 Receives Positive Opinion 67 JOULFERON 67 European Medicines Evaluation 67 IND Investigational New 67 Pirfenidone 67 sNDA 67 Pivotal Phase III 67 Mutual Recognition Procedure 67 CONBRIZA 67 Civacir 67 Trobalt 66 FIRAZYR 66 StaphVAX R 66 Clinical Trial Application 66 GATTEX TM 66 Raptiva R 66 Cellegesic 66 Premarket Approval Application 66 NDA Submission 66 Files Investigational 66 Icatibant 66 OMP designation 66 Fast Track Status 66 Rhucin 66 Premarket Approval PMA 66 Orphan Status 66 Medicinal Products EMEA 66 Positive Opinion 66 Junovan 66 Augment Bone Graft 66 Pivotal Trial 66 COMFORT II 65 Centralized Procedure 65 severe hypercholesterolemia 65 FOLOTYN ® 65 Supplemental Biologics License Application 65 Investigational Device Exemption 65 SYCREST 65 ATryn R 65 Preotact 65 Ceplene 65 Evoltra TM 65 Market Approval PMA 65 registrational 65 Application BLA 65 liver resection surgeries 65 Zenpep 65 Orphan Medicinal Product 65 Telavancin 65 Certican 64 PREOS R 64 Dyloject TM 64 Romiplostim 64 orphan medicinal product 64 GTC recombinant human 64 Receives Marketing Authorization 64 Fast Track Designation 64 Voraxaze 64 GTC recombinant form 64 CHMP recommendation 64 Entereg TM 64 FDA approvable letter 64 Patient Enrollment 64 BENLYSTA 64 Receives Orphan Drug Designation 64 Nexavar ® 64 Orphan Drug designation 64 Ranolazine 64 Adenuric R 64 Raptiva ® 64 Increlex R 64 Esbriet pirfenidone 64 PDUFA Date 64 BRILINTA 64 application sNDA 64 Glybera R 64 MEPACT 64 Approvable Letter 64 FDA Complete Response 64 Dacogen injection 64 lorcaserin NDA 63 oral ridaforolimus 63 SEBIVO 63 FIRMAGON R 63 VIVITROL ® 63 Preotact R 63 supplemental biologics 63 PMA submission 63 Pixuvri 63 ezogabine 63 Alitretinoin 63 Alvesco R 63 commercialize oritavancin 63 CHMP opinion 63 Drug Submission 63 Orphan Drug Designation 63 Phase IIIb clinical 63 Synvisc One 63 refractory chronic lymphocytic 63 Zebinix R 63 sNDA submission 63 Ruconest 63 Tostrex 63 Zalbin 63 Pixantrone 63 Expanded Indication 63 Decentralized Procedure 63 ruxolitinib 63 Zenvia ™ 63 Oracea TM 63 Ixempra 63 Angiox 63 Ventavis 63 REPLAGAL 63 Cimzia ® certolizumab pegol 63 CIP TRAMADOL ER 63 Phase III Trial 63 Personalized Immunotherapy 63 Entereg R 63 rolling Biologics License 63 Eloxatin ® 63 Joulferon 63 Pivotal Clinical Trial 63 hoFH 63 Pivotal Study 63 TEMODAL 63 Levoleucovorin 63 Mepact 63 Golimumab 63 Phase III Clinical Trials 63 Angiox ® 63 SNT MC# 63 Loramyc R 63 Luveniq 63 PREOS 63 MOZOBIL 63 acyclovir Lauriad R 63 eprodisate KIACTA TM 63 Somatuline R Autogel R 62 Scientific Advice 62 human C1 inhibitor 62 Torisel 62 Evoltra 62 ZEGERID Capsules 62 Roflumilast 62 NDA submission 62 Investigational Device Exemption IDE 62 Ceftobiprole 62 Esbriet ® 62 Granted Orphan Drug 62 Phase IIb Trial 62 Aryplase 62 Keppra ® XR 62 IND Application 62 ATPace TM 62 Fast Track designations 62 Oracea ® 62 phase IIb clinical 62 BENLYSTA ® 62 L MTP PE 62 Accelerated Approval 62 ONGLYZA ™ 62 Prestara TM 62 Dupuytren Contracture 62 Cimzia TM 62 Syndrome LEMS 62 Plenaxis R 62 Peginterferon alfa 2b 62 Dalbavancin 62 Soliris TM eculizumab 62 APF# NDA 62 Receives Orphan Drug 62 Loramyc 62 Orphan Designation 62 Lambert Eaton Myasthenic 62 Zingo TM 62 Genasense ® 62 Tezampanel 62 INDs 62 Pafuramidine 62 FUSILEV ® 62 Nebido 62 Nabi HB Intravenous 62 Completes Patient Enrollment 62 Cimzia ® 62 Cladribine Tablets 62 TORISEL 62 Phase 2b Clinical Trial 62 IND submission 62 MEZAVANT 62 Corlux 62 PROVIGIL 62 Submits Supplemental 62 HP Acthar Gel repository 62 RELISTOR ® 62 Phase IIb Clinical Trial 62 Ceflatonin 62 octreotide implant 62 Loramyc ® 62 Jevtana 62 human antithrombin 62 OMAPRO ™ 62 Toctino R 62 Mylan Receives Approval 61 Kit CD# positive 61 Firazyr 61 Brilique 61 REVLIMID R 61 XIAFLEX TM 61 ANTEGREN 61 ZEGERID Chewable Tablets 61 Allovectin 7 r 61 methylnaltrexone bromide 61 ATryn ® 61 taliglucerase alfa 61 MONOVISC 61 THELIN 61 sorafenib tablets 61 NOXAFIL 61 Submits NDA 61 Oral Calcitonin 61 Complete Response letter 61 PROVENGE sipuleucel T 61 Ranexa R 61 Satraplatin 61 phase IIb trial 61 pseudobulbar affect PBA 61 REBETOL combination therapy 61 PIX# trial 61 ZALBIN 61 Intravenous Hepatitis B 61 Evoltra ® 61 Biologics Licensing 61 Psoriasis Drug 61 DORIBAX 61 ALVESCO R 61 NEBIDO 61 Orphan Drug designations 61 T Pred 61 miconazole MBT 61 Fodosine 61 histamine dihydrochloride 61 Neupro ® 61 Febuxostat 61 Investigational 61 prGCD 61 granted Ortec 61 silodosin 61 ATryn ® GTC recombinant 61 Phase IIIb study 61 Impax ANDA 61 highly purified pasteurized 61 Meets Primary Endpoint 61 Approvable 61 Initiate Clinical Trial 61 IND Filing 61 Priority Review 61 IV acetaminophen 61 ADVEXIN 61 rasagiline tablets 61 Marketing Approval PMA 61 methylnaltrexone 61 BYETTA ® 61 Cutaneous T 61 Accelerated Assessment 61 intravenous acetaminophen 61 Phase IIa trial 61 Drug Eluting Stent System 61 LUVENIQ 61 Nexavar sorafenib 61 Cladribine 61 Announces Tentative Approval 61 DASISION 61 Generic Version 61 Methylnaltrexone 61 Ceplene R 61 Sycrest 61 R bendamustine hydrochloride 61 ENTEREG ® 61 Rhucin ® recombinant 61 PROSTASCINT R 61 Evoltra R 61 interferon gamma 1b 61 Safinamide 61 SmPC 61 Avastin bevacizumab 61 Yondelis ® 61 Onco TCS 61 Metastatic Colorectal Cancer 61 ORENCIA R 61 albinterferon alfa 2b 61 Cloretazine ® 60 IL# PE#QQR 60 Movectro 60 Saforis 60 docetaxel Taxotere ® 60 Toctino ® 60 Vimpat ® lacosamide 60 ABILIFY R 60 Severe Sepsis 60 TELINTRA 60 European Medicines Agency 60 eltrombopag 60 Ceflatonin ® 60 Tasigna nilotinib 60 VALSTAR 60 Pivotal Phase 60 MyVax R 60 Viviant 60 Patient Enrolment 60 Fibrillex TM 60 SUTENT ® 60 LibiGel ® 60 testosterone gel LibiGel 60 sumatriptan DosePro 60 Xyrem ® 60 TAXUS Element Stent System 60 PrevOnco 60 Pegloticase 60 Phase 2a Trial 60 CERVARIX R 60 Intermezzo ® NDA 60 oral methylnaltrexone 60 Renvela 60 Naglazyme 60 Troxatyl 60 Glybera 60 Vion Pharmaceuticals 60 Advagraf 60 Kuvan R 60 XIAFLEX ™ 60 bazedoxifene 60 Focetria 60 AVASTIN 60 Grants Orphan Drug 60 Mycograb 60 post operative ileus 60 Premarket Approval 60 FACTIVE R gemifloxacin 60 EFAPROXYN 60 PROVENGE ® 60 Clolar ® 60 SUMAVEL 60 Bayer Onyx 60 Sagent Pharmaceuticals Announces 60 Omigard TM 60 Firazyr ® 60 SPRYCEL ® 60 ARCOXIA 60 R lenalidomide 60 Bronchitol 60 balsalazide tablet 60 FRDA 60 Ereska 60 Ganite ® 60 STELARA TM 60 Firdapse 60 Zactima 60 Amrubicin 60 Onrigin 60 Immune Globulin Human 60 Azilect ® 60 Soliris eculizumab 60 GATTEX ™ 60 Ambrisentan 60 BEMA Fentanyl 60 OFIRMEV 60 Bendamustine 60 FlutiformTM 60 Dapagliflozin 60 Phase III clinical trials 60 Diabetic Macular Edema 60 Vasovist 60 PROGENSA R 60 PROMACTA 60 Esbriet 60 Panzem R 60 VISICOL R 60 Oracea 60 Frova ® 60 EOquin 60 Somatuline Depot 60 Somatuline R Depot 60 ORENCIA ® 60 Santhera 60 ANDA Filing 60 Phase III clinical 60 CryoSeal FS System 60 NDA resubmission 60 investigational humanized monoclonal antibody 60 sapropterin dihydrochloride 60 CE Marked 60 LibiGel NDA 60 Kuvan TM sapropterin 60 Fortigel 60 Clevudine 60 Acetavance TM 60 ITAX 60 ROTATEQ 60 Investigational Compound 60 approvable letters 60 TRANSDUR Sufentanil 60 registrational trial 60 Desvenlafaxine 60 cUTI 60 INSPIRE Trial Phase III 60 THALOMID 60 Clofarabine 60 ELIQUIS 60 Serostim ® 60 Ciclesonide 60 submitted Marketing Authorization 60 alogliptin 60 ZEVALIN ® 60 Kamada AAT 60 virus HCV protease inhibitor 60 Omigard 60 #D#C# 60 Exocrine Pancreatic Insufficiency 60 Amitiza 60 Augment Injectable 60 Phase Ib study 60 Orphan Drug 60 Prospective Randomized 60 FASLODEX 60 SILENOR TM 60 Barr ANDA 60 Rectogesic 60 ZOLINZA 60 Velcade bortezomib 60 Thalidomide Pharmion 60 HoFH 60 Cimzia certolizumab pegol 60 Pfizer Sutent 60 miconazole Lauriad R 60 Clinical Trial Results 60 Augment TM 59 Tracleer r 59 PDX pralatrexate 59 Rifaximin 59 Genasense R 59 Fast Track designation 59 CAMPATH R 59 markets HP Acthar 59 UPLYSO 59 Prostate AdenoCarcinoma Treatment 59 Bayer Nexavar 59 Paliperidone Palmitate 59 DC Bead 59 OPAXIO 59 nasal calcitonin product 59 Relistor 59 MK #B 59 Uvidem 59 HepaGam B TM 59 Flutiform ™ 59 TYGACIL 59 Neupro R 59 GRAS notification 59 TYKERB 59 Bazedoxifene 59 Zytiga 59 Gleevec Glivec 59 Mozobil 59 Files IND 59 FDA Orphan Drug 59 Phase III pivotal 59 k Premarket Notification 59 KRYSTEXXA TM pegloticase 59 mesylate tablets 59 CHMP 59 Abstral 59 Phenoptin 59 Taxotere ® 59 Expedited Review 59 Orphan designation 59 Cetrorelix 59 POSIDUR TM 59 StaphVAX 59 Bonefos 59 Phase 2b trial 59 Release Capsules 59 mifamurtide 59 Noxafil 59 Alogliptin 59 Kynapid 59 Triage Stroke Panel 59 Zenvia Phase III 59 ceftobiprole 59 Vascular Wrap TM 59 Tekturna HCT 59 Anturol TM 59 Ofatumumab 59 Targretin capsules 59 Deferiprone 59 Japanese Encephalitis vaccine 59 Adjuvant Treatment 59 Tarceva TM 59 Ticagrelor 59 sublingual tablets 59 NUEDEXTA ™ 59 Telatinib 59 Act PDUFA date 59 Entocort 59 HFA MDI 59 Velaglucerase Alfa 59 Aclasta Reclast 59 indiplon capsules 59 vinorelbine emulsion 59 Product Characteristics 59 Decentralized Procedure DCP 59 Alvesco 59 dextromethorphan quinidine 59 RANK Ligand inhibitor 59 Drug Application 59 REVLIMID lenalidomide 59 pivotal bioequivalence 59 Fludara ® 59 confirmatory Phase III 59 Exelbine NDA 59 XAGRID 59 sitaxsentan sodium 59 RSR# 59 Initiate Phase 59 vilazodone 59 acyclovir Lauriad ® 59 Luveris 59 YONDELIS 59 paliperidone palmitate 59 Promacta 59 pivotal Phase III 59 Saphris 59 subcutaneous RELISTOR 59 Increlex ® 59 Firdapse ™ amifampridine phosphate 59 DepoDur 59 Initiates Enrollment 59 Advanced Melanoma 59 DAYTRANA TM 59 Combination REOLYSIN R 59 ULTRASE 59 TYZEKA 59 Swissmedic 59 Alvesco ® 59 aztreonam lysine 59 Zevtera ™ 59 Biologics License Applications 59 Octreolin 59 Replagal 59 Augment ™ 59 Eliquis 59 sNDAs 59 SABER ™ 59 Tracleer R 59 PANVAC VF 59 severe gastroparesis 59 desvenlafaxine 59 Approvable letter 59 Contrave NDA 59 motexafin gadolinium Injection 59 SPARLON 59 IMA# 59 Onsolis 59 Plicera 59 corticotropin injection 59 IND CTA 59 Glatiramer Acetate 59 Vandetanib 59 Initiates Phase III 59 Renvela ® 59 Bone Graft 59 Efficacy Results 59 ketolide antibiotic 59 Flutiform TM 59 Tesamorelin 59 velaglucerase alfa 59 ixabepilone 59 Hycamtin 59 ZEFTERA ™ 59 nanofiltered plasma derived 59 AstraZeneca Symbicort 59 RoACTEMRA 59 Advexin 59 Kiacta 59 Ganite R 59 Study Evaluating 59 Cerepro ® 59 investigational pan BCR 59 LEUKINE 59 Pulmonary Arterial Hypertension 59 granulated mesalamine 59 AZILECT ® 59 generation purine nucleoside 59 Drug Candidate 59 Iluvien ® 59 Resubmission 59 cinacalcet HCl 59 CIMZIA r 59 Eltrombopag 59 efalizumab 59 ONGLYZA TM 59 Afinitor ® 59 Bifeprunox 59 Firdapse TM amifampridine phosphate 59 Brentuximab Vedotin SGN 59 SUCCEED trial 59 Mycamine 59 Zavesca r 59 Mirapexin 59 fluvoxamine maleate 59 XIAPEX ® 59 phase III isavuconazole 59 Lubiprostone 59 Dyloject 59 MOVIPREP R 59 BLOOM DM 59 CDP# 59 diabetic neuropathic pain 59 PNP inhibitor 59 cell lymphoma CTCL 58 ARIXTRA R 58 Sestamibi 58 IMPACT IMmunotherapy 58 clofarabine 58 Actemra tocilizumab 58 Schizophrenia Drug 58 investigational antiplatelet agent 58 JZP 6 58 CRMD# 58 human lactoferrin 58 PEGINTRON TM 58 RELISTOR 58 Exelbine 58 VPRIV 58 telavancin NDA 58 Nivestim 58 Eraxis 58 pralatrexate 58 Phase Ib II 58 refractory Hodgkin lymphoma 58 BioDelivery Sciences 58 LHRH antagonist 58 NEBIDO R 58 Zenvia TM 58 Emezine 58 Tamibarotene 58 AZILECT R 58 Ocrelizumab 58 Restanza 58 Clolar 58 INFUSE R 58 sunitinib malate 58 diabetic peripheral neuropathic pain 58 Zelrix 58 Sanvar R 58 EGRIFTA TM 58 Receives Approvable Letter 58 Increlex TM 58 Orapred ODT 58 Phase Ib IIa 58 sNDA filing 58 vernakalant hydrochloride 58 Cimzia 58 Xcytrin R 58 Romidepsin 58 UCB Cimzia 58 Long Term Efficacy 58 oxymorphone ER 58 Ceflatonin R 58 Xolegel 58 Entereg 58 BLP# Liposome Vaccine 58 Oracea R 58 Patients Treated With 58 lucinactant 58 submitted Biologics License 58 NUVIGIL 58 Topotecan 58 Submits Investigational 58 PEGylated anti 58 LE SN# 58 Neuromodulation System 58 Ustekinumab 58 IIa trial 58 lexidronam injection 58 Camvia 58 XL# anticancer compounds 58 OvaRex ® MAb 58 Investigational Treatment 58 teduglutide 58 bifeprunox 58 ALN PCS 58 PDUFA date 58 Actemra 58 cutaneous T 58 Auxilium Pharma 58 QNEXA ® 58 Eculizumab 58 Aviptadil 58 SCHWARZ PHARMA 58 submit Biologics License 58 TheraCIM 58 Inhalation Aerosol 58 LUMINATE 58 unique alkylating agent 58 AMITIZA R 58 tiapamil 58 Onalta ™ 58 oropharyngeal candidiasis 58 Campath ® 58 BARACLUDE R 58 Antegren 58 FavId 58 Linjeta TM 58 Arzerra TM 58 SinuNase TM 58 peginesatide 58 myelodysplastic myeloproliferative diseases 58 Adalimumab 58 Treanda 58 BRINAVESS 58 CAELYX 58 Complete Response Letter 58 FOLOTYN 58 Phase III Pivotal 58 Exalgo 58 Retacrit 58 MAGE A3 ASCI 58 rilonacept 58 Basilea Toctino R 58 omacetaxine 58 Revolade 58 Zorbtive TM 58 ELAPRASE 58 Irinotecan 58 SILENOR 58 LEVADEX ™ 58 Extavia 58 Qutenza 58 synthetic lipoglycopeptide antibiotic 58 Taxotere R 58 REVLIMID ® 58 FOSAMAX PLUS D 58 Keppra ® levetiracetam 58 MoxDuo IR 58 Hexvix 58 Phase 1b trial 58 oral prodrug 58 TroVax ® 58 cutaneous T cell 58 Wyeth Torisel 58 TORISEL TM 58 Initiates Phase II 58 Milestone Payments 58 C1 Inhibitor 58 VIAject R 58 Li Fraumeni Syndrome 58 SAR# [004] 58 Phase IIb trial 58 Phase III Trials 58 granted orphan medicinal 58 Prodarsan R 58 Soriatane 58 LIALDA 58 Lenocta 58 LUCASSIN 58 CoFactor 58 Oncoscience AG 58 ONSOLIS 58 Ketotransdel 58 LEVADEX TM 58 Kuvan 58 Ramelteon 58 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 58 Friedreich Ataxia FRDA 58 FOSRENOL 58 ACOMPLIA R 58 Submits Biologics License Application 58 OLEPTRO TM 58 JAK Inhibitor 58 Tekamlo 58 tafamidis 58 Vitrasert R 58 Polyphenon ® E 58 Metformin GR 58 Filgrastim 58 nonclinical studies 58 GEM #S 58 cSSTI 58 R sorafenib tablets 58 CLARITY study 58 amifampridine phosphate 58 PROMUS TM 58 Acetavance 58 Cinryze ™ 58 Topical Interferon Alpha 2b 58 Phase Ib 58 Vimpat R 58 Vimpat lacosamide 58 Testosterone Gel 58 Cinryze TM 58 Telzir 58 ® decitabine 58 postoperative ileus POI 58 SEASONALE R 58 gastrointestinal disorders characterized 58 Valtropin 58 BYDUREON 58 Mimpara 58 midstage studies 58 ThermoDox ® 58 HuMax CD4 58 SEROQUEL XR 58 Fabry Disease 58 BRIM3 58 romiplostim 58 BioSTAR R 58 ENRICH trial 58 Lung Cancer Drug 58 Drug Applications ANDAs 58 ZEGERID Powder 58 SEPET 58 Vernakalant 58 vinflunine 58 Pralatrexate 58 Phase 1b Clinical Trial 58 Aloxi ® 58 Submits Response 58 Cleviprex TM clevidipine 58 Pruvel 58 ZADAXIN ® 57 axitinib 57 Vibativ 57 known teratogen substance 57 TREANDA 57 molecular imaging radiopharmaceutical 57 Eszopiclone 57 APTIMA HPV assay 57 OMNARIS HFA 57 ATRIPLA 57 PrevOnco ™ 57 TRISENOX 57 diarrhea predominant irritable 57 opioid induced constipation OIC 57 Tyvaso 57 cladribine 57 Initiate Phase III 57 Acute Attacks 57 PhosLo 57 maribavir 57 Vicriviroc 57 FUSILEV 57 Cimzia R 57 BAY #-# 57 Aloxi R 57 lymphoma CTCL 57 Hematide ™ 57 FDA APPROVES 57 LymphoStat B TM 57 cervical cancer vaccine Cervarix 57 iloprost Inhalation Solution 57 Maribavir 57 QNEXA 57 Stavzor 57 Rasilamlo 57 Fondaparinux 57 orBec 57 Demonstrates Positive 57 Tracleer ® bosentan 57 TRANSDUR ™ 57 novel oral anticoagulant 57 Marqibo 57 Aloxi Injection 57 JAK inhibitor 57 include Phenoptin TM 57 FDA Investigational Device 57 Lenalidomide 57 Aztreonam Lysine 57 Certolizumab pegol 57 Degarelix 57 JAK2 Inhibitor 57 PROMACTA ® 57 Pazopanib 57 receptor tyrosine kinase inhibitor 57 Sebivo 57 Ceplene ® 57 Phase 2b Study 57 Alair System 57 omacetaxine mepesuccinate 57 DYNEPO 57 MabCampath 57 Manja Bouman CEO 57 Fx #A 57 Preos 57 FAME Study 57 Vitaros 57 rThrombin 57 Investigational Drug 57 Ceplene ® histamine dihydrochloride 57 proprietary transdermal patch 57 Aridol 57 Complicated Skin 57 Angiox R 57 Metformin HCl 57 Phase #/#a trial 57 Octreotide 57 Horizant 57 Stimuvax R 57 Cerepro 57 JZP 57 Pirespa 57 Combidex 57 CORTOSS 57 Arzerra ofatumumab 57 REPEL CV 57 OLpur TM H2H 57 Keppra XR 57 ambrisentan 57 PLK1 SNALP 57 k premarket 57 VIMOVO 57 Sonolith i move 57 Amigal TM 57 Phase IIa 57 Hematological Malignancies 57 REMOXY NDA 57 APPRAISE 57 Ridaforolimus 57 OsseoFix 57 Liberte TM 57 N acetylgalactosamine 6 57 relapsed refractory multiple myeloma 57 Liprotamase 57 Aurexis 57 non metastatic osteosarcoma 57 post herpetic neuralgia PHN 57 Cethromycin 57 Dose Ranging Study 57 oritavancin 57 Elagolix 57 Extina 57 IV APAP 57 Phase #b/#a clinical 57 Alinia 57 Vimovo 57 Tyverb 57 Presents Positive 57 NOVARTIS 57 Zensana 57 rheumatoid arthritis psoriatic arthritis 57 Teva Provides Update 57 Rasilez HCT 57 Generic Lovenox 57 markets Gelclair R 57 Loxapine 57 SUPPRELIN R LA 57 placebo controlled Phase III 57 COLAZAL R 57 Arixtra 57 Feraheme ® 57 XIAPEX 57 Kiadis Pharma 57 Hepatocellular Carcinoma 57 Phase III trials 57 miconazole Lauriad ® 57 Vectibix panitumumab 57 By JAMAAL ABDUL 57 TAXUS Element Paclitaxel Eluting 57 CLIA waiver

Back to home page